0001171843-18-007417.txt : 20181031 0001171843-18-007417.hdr.sgml : 20181031 20181031160522 ACCESSION NUMBER: 0001171843-18-007417 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20181031 FILED AS OF DATE: 20181031 DATE AS OF CHANGE: 20181031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aeterna Zentaris Inc. CENTRAL INDEX KEY: 0001113423 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38064 FILM NUMBER: 181150342 BUSINESS ADDRESS: STREET 1: C/O STIKEMAN ELLIOTT LLP STREET 2: 1155 RENE-LEVESQUE BLVD. WEST, 41ST FLR CITY: MONTREAL STATE: A8 ZIP: H3B 3V2 BUSINESS PHONE: 843-900-3201 MAIL ADDRESS: STREET 1: C/O STIKEMAN ELLIOTT LLP STREET 2: 1155 RENE-LEVESQUE BLVD. WEST, 41ST FLR CITY: MONTREAL STATE: A8 ZIP: H3B 3V2 FORMER COMPANY: FORMER CONFORMED NAME: AETERNA LABORATORIES INC DATE OF NAME CHANGE: 20000503 6-K 1 f6k_103118.htm FORM 6-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2018

Commission File Number: 0-30752

Aeterna Zentaris Inc.
(Translation of registrant's name into English)

315 Sigma Drive, Suite 302D Summerville, South Carolina, USA 29486
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☒

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-______.

On October 31, 2018, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated October 31, 2018

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Aeterna Zentaris Inc.
		(Registrant)


Date: October 31, 2018		/s/ MICHAEL V. WARD
		Michael V. Ward
		CEO

EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling

EXHIBIT 99.1

Aeterna Zentaris to Announce Third Quarter 2018 Financial and Operating Results on November 6, 2018

CHARLESTON, S.C., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS) will announce its third quarter 2018 financial and operating results after market close on Tuesday, November 6, 2018. The Company will host a conference call to discuss these results on Wednesday, November 7, 2018 at 8:30 a.m. Eastern Time.

Participants may access the conference call by telephone using the following numbers:

Toll-Free: 877-407-8029, Confirmation #13684540
Toll: 201-689-8029, Confirmation # 13684540

A replay will also be available on the Company’s website for a period of 30 days.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an oral ghrelin receptor agonist, to be administered in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.zentaris.com.

Contact:

Leslie Auld
Chief Financial Officer
Aeterna Zentaris Inc.
IR@aezsinc.com
843-900-3201